4/A: Citius Oncology Director Granted 300,000 RSUs

Citius Oncology's Director, Robert Joseph Smith, was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Summary

• Robert Joseph Smith, a Director of Citius Oncology, Inc. (CTOR), was granted 300,000 shares of Common Stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was September 19, 2025.
• The RSUs were granted at a price of $0 per unit.
• The shares underlying these restricted stock units will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Mr. Smith's continuous service to Citius Oncology, Inc. or a Related Entity as of the applicable vesting date.
• Following this transaction, Robert Joseph Smith beneficially owns 300,000 shares directly.

Sentiment

Score: 5

Explanation: This filing is a routine report of an insider transaction (equity grant) and does not contain information that would significantly alter the company's fundamental outlook or market sentiment. It is a neutral event reflecting standard compensation practices.

Positives

• The grant of restricted stock units aligns the interests of Director Robert Joseph Smith with those of shareholders, as the value of his compensation is tied to the company's future stock performance.
• Equity compensation is a standard practice to attract and retain experienced directors in the biotechnology sector.

Negatives

• No specific negative information is detailed in this routine insider transaction report.

Risks

• The vesting of the 300,000 restricted stock units is subject to Robert Joseph Smith's continuous service to Citius Oncology, Inc. or a Related Entity, posing a risk to the reporting person if service is terminated.
• No company-specific risks are detailed in this filing.

Future Outlook

The future outlook for the reporting person includes the potential vesting of 300,000 restricted stock units on September 19, 2028, contingent on continuous service to Citius Oncology, Inc.

Industry Context

The grant of restricted stock units to a director is a common form of equity compensation in the biotechnology and pharmaceutical industries. This practice is widely used to incentivize long-term commitment and align the interests of key personnel with shareholder value creation, particularly in companies like Citius Oncology, Inc. which are often focused on long-term drug development cycles.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of director compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity to incentivize leadership.
• The vesting schedule, tied to continuous service over three years, is also a common mechanism designed to promote long-term retention and commitment, aligning with typical industry benchmarks for executive and director equity awards.

Related Party Transactions

• Grant of 300,000 restricted stock units to Robert Joseph Smith, a Director of Citius Oncology, Inc., as a form of compensation, which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: The grant of RSUs represents potential future dilution upon vesting, but also aims to align the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The restricted stock units are scheduled to vest in full on September 19, 2028, subject to the director's continuous service.

Key Dates

Keywords

Citius Oncology, CTOR, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Form 4/A